© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.
March 17th 2021
The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.
Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.
Third-line treatment recommendations for patients with GIST and a discussion on side effect management.
The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.
March 24th 2021
The experts present and discuss a case of a patient with KIT exon 9-mutated GIST, an including an overview of surgical options.
The experts discuss the use of imatinib in patients with KIT exon 9-mutated GIST. Additionally, they comment on surgical options for patients with GIST.
Key opinion leaders consider later lines of therapy in metastatic KIT exon 9–mutated GIST and how to monitor and mitigate toxicities.
A panel of experts review the VOYAGER and INTRIGUE trials.
March 31st 2021
Presentation and considerations for a case of PDGFRα D842V-mutated GIST.
Experts discuss KIT and PDGFRα D842V-mutations in GIST and present the NAVIGATOR trial.